Peptide Comparison
5-Amino-1MQvsRetatrutide
A small-molecule NNMT inhibitor studied in animals for fat loss and NAD+ metabolism.
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
At a Glance
Quick
comparison
Dose Range
5-Amino-1MQ
N/A
Retatrutide
4–8 mg
Frequency
5-Amino-1MQ
No human dose established
Retatrutide
Once weekly
Administration
5-Amino-1MQ
Subcutaneous injection
Retatrutide
Subcutaneous injection
Cycle Length
5-Amino-1MQ
8-12 weeks (community-reported; no human trial data)
Retatrutide
12+ weeks
Onset Speed
5-Amino-1MQ
Not established in humans; gradual over weeks in animal studies
Retatrutide
Moderate (1-2 weeks)
Evidence Level
5-Amino-1MQ
Preclinical only (animal and lab studies; no human trials)
Retatrutide
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Fat and weight reduction
Metabolic markers
NAD+ / cellular energy
Human evidence
Weight Loss Power
Metabolic Health
Appetite Control
Technical Data
Compound
specifications
5-Amino-1MQ
Molecular Formula
C10H11N2+ (cation); commonly supplied as the iodide salt (C10H11IN2)
Molecular Weight
159.21 g/mol (cation); 286.11 g/mol (iodide salt)
Half-Life
Not established in humans; preclinical rodent data suggest a few hours (compound is membrane-permeable and orally active)
Bioavailability
Orally bioavailable in animal studies (high membrane permeability shown by PAMPA and Caco-2 assays); human data not established
CAS Number
42464-96-0 (salt form)
Retatrutide
Molecular Formula
C221H342N46O68
Molecular Weight
4731 g/mol
Half-Life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS Number
2381089-83-2
Protocols
Dosing
tiers
5-Amino-1MQ
Retatrutide
Applications
Best
suited for
5-Amino-1MQ
Fat loss research
The clearest, most repeated finding: obese mice lost body weight and fat mass on 5-Amino-1MQ without eating less [1][2]. This is the main reason people are interested — though it is animal data, not human proof.
Metabolic health support
In mice, it improved blood sugar, insulin, and liver fat [2]. Researchers see NNMT inhibition as a promising angle for metabolic syndrome [4].
NAD+ and cellular energy science
By blocking NNMT, it raises NAD+ and SAM inside cells, which supports how cells make and use energy [1][4]. This makes it interesting to people studying aging and metabolism.
Retatrutide
Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Safety Profile
Side
effects
5-Amino-1MQ
Common
- No verified human side effects
- Mild nausea or headache (community-reported)
Uncommon
- Fatigue or flushing (community-reported)
Serious
- Possible off-target MAO-A effects (theoretical)
- Unknown long-term and human risks
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Research Status
Safety
& evidence
5-Amino-1MQ
Evidence Level
Preclinical only (animal and lab studies; no human trials)
FDA Status
Research compound — not FDA approved
Safety Overview
The honest picture: nobody has run a human safety trial on 5-Amino-1MQ, so everything below is from mice and cultured cells. In the 11-day mouse study, 9 treated animals lost 2.0 ± 0.6 g of body weight (about 5.1% from baseline) while 9 controls gained 0.6 ± 0.4 g, with no difference in food intake and no observable adverse effects reported [1]. The tolerability ceiling people quote comes from a dose-escalation study spanning 10 to 150 mg/kg/day in TWO mice, where 60 mg/kg/day produced no observable adverse effects [1] — a denominator worth seeing before treating it as a safety margin. In cultured pre-adipocytes the compound is cytotoxic at high concentration: no effect on viability at 10 µM, modest cytotoxicity from 100 to 300 µM, and roughly 40% loss of viability at 600 µM [1]. Lab screening also found off-target inhibition of monoamine oxidase-A at higher concentrations [2]. Short studies in mice cannot rule out problems that appear over months or years in people. Treat this as an experimental compound and talk to a doctor first, particularly if you take any medication.
Contraindications
- xNo human safety data exists — all evidence is from animals and lab work
- xPregnancy or breastfeeding
- xUse with MAO-A-sensitive medications, given off-target MAO-A inhibition seen in lab screening [2]
Retatrutide
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- xPregnancy or planning to become pregnant
- xHistory of severe pancreatitis
- xKnown allergy to GLP-1 receptor agonists
Decision Guide
Which is
right for you?
Choose 5-Amino-1MQ if...
- Fat loss (research context)
- Metabolic health support
- NAD+ and cellular energy metabolism
Choose Retatrutide if...
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization